RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
US$ 23,85
arrow_downward
-1,04%(-0,25) 1D
27 apr, 15:07:00 GMT-4 · USD
search
Alle symbolen
1D
5D
1M
6M
YTD
1J
5J
MAX
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor RARE genereren…
Openen
US$ 24,15
Hoog
US$ 25,05
Laag
US$ 23,78
Beursw.
2,34 mld.
Gem. vol.
2,04 mln.
Volume
850,28K
52 wk hoog
US$ 42,37
52 wk laag
US$ 18,29
WPA
US$ -5,83
Bèta
0,25
Uitstaande aandelen
98,32 mln.
Aantal medewerkers
1K
Nieuwsartikelen
Van bronnen op internet
Yahoo Finance
·
2 dagen geleden
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Profiel
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Over Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Medewerkers1,37K
Opgericht2010
HoofdkantoorNovato, Californië, Verenigde Staten
Sector-
Websiteultragenyx.com
AI-content kan fouten bevatten. Meer informatie